Latest filing published 03 Aug 2026 for Hemostemix Inc., €20k.
Two companies listed on the Toronto Stock Exchange make up Peter Alan Lacey's record: Hemostemix Inc. (27 filings, as a director) and Nexera Energy Inc. (4, as a holder of more than 10% of the securities). Among 31 filings there are 9 open-market purchases worth EUR 180,537 (median EUR 18,707) and 7 sales worth EUR 91,731 (median EUR 11,216). Purchases weigh 56% of the open-market trades. The record adds 3 share grants, one option exercise and 11 filings of another kind.
The largest purchases date from 2021: EUR 41,857 on June 14 and EUR 32,679 on March 11, then EUR 23,254 on February 26, 2025. The heaviest sale, EUR 32,457, goes back to April 17, 2020, ahead of EUR 16,523 on February 24, 2025 and EUR 12,372 on February 27, 2025. Late February 2025 thus brings together purchases and sales a few days apart.
Activity is concentrated in 2025 (15 filings) and 2026 (7), against 5 in 2021 and 1 to 2 in the other years. The 7 filings of the past twelve months include neither a purchase nor a sale. Median publication delay: 3 days. Trades by Lacey within 30 days of a colleague at Hemostemix Inc. number 14. Same side: 8. Colleague: Thomas Smeenk.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 42 declarations